Marinus Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 165
- Market Cap
- $80.9M
- Introduction
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
Clinical Trials
28
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)
- Conditions
- Refractory Status Epilepticus
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Marinus Pharmaceuticals
- Registration Number
- NCT05814523
- Locations
- 🇦🇹
Medical University of Innsbruck, Innsbruck, Austria
🇦🇹Kepler University Hospital, Linz, Austria
🇦🇹Kepler Universitätsklinikum GmbH, Linz, Austria
Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)
- Conditions
- Status Epilepticus
- Interventions
- Drug: IV GanaxoloneDrug: IV Placebo
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Marinus Pharmaceuticals
- Registration Number
- NCT05757544
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT05604170
- Locations
- 🇺🇸
Arkansas Children's Research Institute, Little Rock, Arkansas, United States
🇺🇸UCLA Mattel Children's Hospital, TSC Center, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 129
- Registration Number
- NCT05323734
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
🇨🇳Chengdu's Women and Children's Central Hospital, Chengdu, China
Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old
- Conditions
- CDKL5 Deficiency Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Marinus Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT05249556
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Ovid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million
Ovid Therapeutics has entered into a definitive agreement with Immedica Pharma AB to sell its future royalty rights for ganaxolone sales outside China for $7 million in cash.
Immedica Acquires Marinus Pharmaceuticals for $151M, Expanding Rare Disease Portfolio with ZTALMY
Swedish rare disease specialist Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for $151M, strengthening its position in the global rare disease market through a cash tender offer of $0.55 per share.
Marinus Pharmaceuticals Cuts 45% of Workforce After Ganaxolone Trial Failure
Marinus Pharmaceuticals announced a workforce reduction of approximately 45% following disappointing Phase III trial results for oral ganaxolone in tuberous sclerosis complex.
Marinus Pharmaceuticals Focuses on Oral Ganaxolone After Trial Setback
Marinus Pharmaceuticals shifts focus to oral ganaxolone (O-GNX) for tuberous sclerosis complex (TSC) after IV ganaxolone (IV-GNX) fails a Phase 3 trial for refractory status epilepticus (RSE).
Amgen Launches Eylea Biosimilar Pavblu at Discount; GSK Invests $800M in Manufacturing
• Amgen has launched Pavblu, its biosimilar to Regeneron's Eylea, at a 10% discount, pricing it at $1,665 per dose, potentially muting its market impact. • GSK is investing $800 million to expand its manufacturing site in Pennsylvania, focusing on sterile liquid vaccines and medicines production. • Roche and Dyno Therapeutics are collaborating to advance AAV gene therapy vectors for neurological diseases, with Dyno receiving $50 million upfront. • AbbVie and Gideon Richter are partnering to discover novel targets for neuropsychiatric conditions, with Richter receiving $25 million upfront.
Marinus Pharmaceuticals' Ganaxolone Fails Primary Endpoint in Phase III TSC Trial
Marinus Pharmaceuticals' Phase III TrustTSC trial of oral ganaxolone for tuberous sclerosis complex (TSC)-associated seizures did not meet its primary endpoint.
Phase 3 Trial of Oral Ganaxolone Fails to Meet Primary Endpoint in Tuberous Sclerosis Complex
Marinus Pharmaceuticals' Phase 3 TrustTSC trial evaluating oral ganaxolone for tuberous sclerosis complex (TSC)-associated seizures did not meet its primary endpoint.
Marinus Pharmaceuticals' Ganaxolone Fails Phase 3 Trial for Tuberous Sclerosis Complex
Marinus Pharmaceuticals' Phase 3 TrustTSC trial of oral ganaxolone for tuberous sclerosis complex (TSC)-associated seizures did not meet its primary endpoint.
Ganaxolone Shows Promise in Phase III RAISE Trial for Refractory Status Epilepticus
Marinus Pharmaceuticals' RAISE trial evaluated IV ganaxolone for refractory status epilepticus (RSE), meeting one co-primary endpoint.
Marinus Pharmaceuticals Highlights ZTALMY® Progress in Tuberous Sclerosis Complex
Marinus Pharmaceuticals anticipates Phase 3 TrustTSC trial results for ZTALMY® in tuberous sclerosis complex (TSC) in Q4 2024, with NDA filing targeted for April 2025.